EGFR and non-small cell lung carcinoma: Our results suggest that erlotinib, but not a 4G EGFR-TKI, may be the most suitable second-line TKI for NSCLC after acquisition of resistance to front-line osimertinib, based on its broad activity against secondary EGFR mutations that may emerge after osimertinib treatment failure.